Welcome to
On Feet Nation
Snehal Shaha Online
jack452 Online
Alma Online
MindCypress Online
geekstation Online
jackharry Online
vipin dhiman Online
Larry Online
Posted by Ashley Lopez on April 17, 2024 at 2:22am 0 Comments 0 Likes
London Blue Topaz Jewelry masters in stealing the spotlight with its royal blue hues and reflects a classy appeal, no matter the accessory you choose for yourself. The gem radiates luxury at its peak in every style and never fails to captivate your heart. If you are looking for a Gemstone Jewelry that is spectacular in every regard, London Blue Topaz is definitely worth your love. Pamper yourself with…
ContinuePosted by Snehal Shaha on April 17, 2024 at 2:22am 0 Comments 0 Likes
The Multimodal Imaging Market refers to the global market for medical imaging technologies that utilize multiple imaging modalities to provide comprehensive and complementary information for diagnostic purposes, research, and treatment planning.
As per the recently published report by MarketsandMarkets™, The report "Multimodal Imaging Market by Technology (PET-CT, SPECT-CT, PET-MR, OCT/FMT), Application (Oncology, Cardiology, Brain, Ophthalmology), End User (Hospitals, Diagnostic…
ContinueThe global cephalosporin drugs market was valued at USD 11.6 billion in 2018 and is expected to grow at a CAGR of 5.2% during the forecast period. Cephalosporin may be a bactericidal, broad-spectrum, β-lactam antibiotic originally derived from the fungus Acremonium that's wont to treat bacterial infections like pneumonia, skin infections, streptococcal sore throat, staph infections, tonsillitis, bronchitis, otitis, gonorrhea, et al. It resembles penicillin and hence is employed as an alternative for patients who are allergic to penicillin. a rise in the incidence of the population affected by pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth.
Key Developments in Cephalosporin Drugs Market:
• In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autolus enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 for the treatment of Respiratory Tract Infection (ALL), by the US FDA
• In April 2019, Cellectis received approval from the US FDA to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM).
• In May 2018, Kite Pharma leased a new facility for cell therapy engineering in Europe in the Netherlands with the aim of strengthening its position on the global market for CAR T-cell therapy.
The key leading players in the market include Ranbaxy, Merck, Sandoz, Pfizer, Astellas, Roche, Bristol-Myers Squibb, Abbott, Lupin Pharmaceuticals, Teva Pharmaceuticals, and Glaxo SmithKline.
© 2024 Created by PH the vintage. Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation